See the DrugPatentWatch profile for rexulti
Generic versions of the antidepressant brexpiprazole (Rexulti) are not yet widely available in the United States. The drug's primary patents and market exclusivities are still in effect, preventing generic manufacturers from launching their versions.
When does brexpiprazole's patent protection end?
Brexpiprazole's patent protection is set to expire in the coming years. According to DrugPatentWatch.com, the earliest key patent expiry dates for brexpiprazole are approaching. Information on specific patent expiry dates can be found on platforms like DrugPatentWatch.com [1].
What does patent expiry mean for drug availability?
Once patents expire and any associated market exclusivities are no longer in effect, generic pharmaceutical companies can seek approval from regulatory bodies, such as the U.S. Food and Drug Administration (FDA), to market their own versions of the drug. This typically leads to increased competition and lower prices for the medication.
Who makes Rexulti?
Rexulti is manufactured by Otsuka Pharmaceutical Co., Ltd. and marketed in the United States by its subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. [2].
What are the implications of generic brexpiprazole for patients?
The eventual availability of generic brexpiprazole is expected to make the medication more affordable for patients. Currently, the cost of brand-name Rexulti can be a barrier for some individuals, and generic competition is a common pathway to increased accessibility.
How does brexpiprazole work?
Brexpiprazole is an atypical antipsychotic medication used to treat schizophrenia and as an adjunctive treatment for major depressive disorder. It works by affecting the activity of dopamine and serotonin neurotransmitters in the brain [3].
What are the challenges to generic drug approval?
Besides patent expiry, generic drug approval also depends on demonstrating bioequivalence to the brand-name drug and meeting all regulatory requirements set by agencies like the FDA. The process can take time, even after patent protection has lapsed.
---
Sources:
[1] DrugPatentWatch.com
[2] Otsuka Pharmaceutical Development & Commercialization, Inc.
[3] Rexulti Prescribing Information